-
A batch of ointments was exposed to strictly check the sale of non-drugs in pharmacies
Time of Update: 2021-03-04
It is reported that the Gusu District Market Supervision Bureau, after receiving the inspection recommendations, for retail pharmacies to carry out a special rectification activities.
-
First lupus nephritis (LN) oral drug! Lupkynis, the best-in-class calcium-adjusted neurophosphatase inhibitor, has been approved by the FDA!
Time of Update: 2021-03-04
recently, the company announced that the U.S. Food and Drug Administration (FDA) has approved Lupkynis (voclosporin), a joint background immunosuppressive therapy for the treatment of active lupus nephritis (LN) adult patients.
-
quarters of the new drug sales revenue of 9.5 billion yuan
Time of Update: 2021-03-04
the first three quarters of 2019, Shi Pharmaceutical Group's pharmaceutical business maintained strong growth, with sales revenue of RMB13,387 million, up 35.1% YoY, according to the company's financial results.
-
Generic drugs will accelerate the replacement of the original research drug high-quality generic drug companies to benefit
Time of Update: 2021-03-04
According to the Economic Observer Network reported, recently, the State Information Center, China Economic Information Network released the "2019 Pharmaceutical Industry Development Report - Outlook: strict control of fees, drug prices, innovative
-
R Classes and Methods for SNP Array Data
Time of Update: 2021-03-04
Recently proposed class definitions for high-throughput SNP arrays extend the eSet class.
-
Tiantian Biology and MorphoSys announced the completion of the first patient drug treatment in the TJ2101 clinical study
Time of Update: 2021-03-04
/> phase 1 clinical study was designed to assess the safety, toerability, pharmacodynamics and pharmacodynamics of TJ210/MOR210. TJ210/MOR210 is an innovative monoclonal antibody for complement factor C5a subject 1 (C5aR1) in collaboration
-
Koren's hanging up! Take 15 heavy-weight varieties, 36 over-rated varieties bright eyes, 11 new class 1 drugs, 41 new products on the road
Time of Update: 2021-03-04
Entering 2021, The Colum Pharmaceuticals product line continues to be happy news, 2 injections have been evaluated, 4 injections were approved at that time. just past 2020, Colum Pharmaceuticals has had a lot of gains: 15 varieties have been
-
Hebei consolidates and divides by drug supplements to speed up the construction of medical associations
Time of Update: 2021-03-04
same time, Hebei has accelerated the pace of medical association construction, implemented the functional orientation of various medical and health institutions at all levels, promoted inter-agency collaboration, and promoted the sinking of high-quality medical resources.
-
drugs are about to be approved! 15 in the research of innovative drug projects into the clinical stage
Time of Update: 2021-03-04
cancer, ensartinib, in the second decade. this is a new powerful, highly selective new generation of APK inhibitors, by effectively inhibiting the activity of APK, to inhibit tumor growth. 2020, Nsatinib was approved for listing in China
-
The shortage of cheap drugs has eased this year
Time of Update: 2021-03-04
situation, patients have to spend nearly 100 yuan to buy 25 tablets / bottle of imported drugs. At the end of April, the Beijing Municipal Drug Administration disclosed that the relevant departments and pharmacies have coordinated
-
New anti-inflammatory drugs! AbbVie oral JAK1 inhibitor Rinvoq has been approved by the European Union to treat 2 new rheumatoids!
Time of Update: 2021-03-04
studies, Rinvoq reached the primary endpoint of the ACR20 response compared to a placebo. , 15 mg doses of Rinvoq and Adamo monoantigen showed non-poor effectiveness in treating the ACR20 response at week 12. patients treated with Rinvoq
-
One year market value fell K drug sales in the last 2 years Mercadon 2021 can get back to a game?
Time of Update: 2021-03-04
In 2021, vaccine giant Merca East opened its year with a cold splash of cold water on the development of a "crazy" new crown vaccine. January 25th, Mercedon will stop developing two candidate vaccines V590 and V591 for SARS-CoV-2/COVID-19.
-
New drug for mild asthma! AstraZeneta has been approved ® the ® Drug Administration to treat mild asthma in adults and adolescents over 12 years of age!
Time of Update: 2021-03-04
are not timely and accurate diagnosis and treatment. , up to 30 to 40 percent of people with mild asthma are likely to have severe acute seizures. to effectively control symptoms and reduce the risk of acute onset, early anti-inflammatory
-
A screen to identify drug resistant variants to target-directed anti-cancer agents
Time of Update: 2021-03-04
Using imatinib and BCR/ABL as a paradigm for a drug-target pair, we recently reported a retroviral vector-based screening strategy to identify the spectrum of resistance-conferring mutations.
-
The second batch of volume purchase lists flowed out of generic drugs to kill prices or more violently
Time of Update: 2021-03-04
/> As a result of this news, on November 29th, the share prices of Stone Pharmaceutical Group, Green Leaf Pharmaceuticals, Hengrui Pharmaceuticals and other related pharmaceutical companies fell sharply. "From the current information
-
"Sky-price ticket" limited effect of life-saving drugs cheap medicine cut off the solution
Time of Update: 2021-03-03
for treating acute lymphoblastic leukemia in children, especially during the maintenance period of more than a year, if the drug is stopped, it will greatly affect the long-term survival effect of children. Because the profit is not high
-
K drug small cell lung cancer PHASE III clinical reach PFS endpoint miss OS endpoint
Time of Update: 2021-03-03
results. The results showed that the Keytruda chemotherapy combination achieved a significant increase in the primary endpoint of patients' progress-free survival (PFS) (HR=0.75,95% CI, 0.61-0.91), but missed the primary endpoint of total lifetime (OS
-
The late trial of migraine drugs was successful
Time of Update: 2021-03-03
Axsome's share increased by more than 80 percent last month after the Phase III study of the experimental drug AXS-05 in adults with moderate to severe depression reached its primary endpoint.
-
Key clinical studies of breakthrough drugs for schizophrenia have been successful
Time of Update: 2021-03-03
treatment for schizophrenia, despite their side effects. Key clinical findings published this time support the potential of SEP-363856 as a new treatment for schizophrenia, which has the potential to have a significant positive impact on the public
-
Severe muscle weakness (MG) new drug! The National Drug Administration grants and platinum medicine
Time of Update: 2021-03-03
binding to each other and accelerates the removal of IgG in the body, thus effectively treating autoimmune diseases mediated by pathogenic IgG. available evidence suggests that lower IgG levels in patients with severe muscle weakness (MG
